Highly Complementary Companies to Advance Therapies to Address Unmet Patient Needs Respective Generics Businesses and Endo's Sterile Injectables Business to be Combined and Spun Off as an Independent Company with Target Date in the Fourth Quarter of 2025 New York Stock Exchange (NYSE) Listing of Branded Company Following Spin-off DUBLIN, Aug. 1, 2025 /PRNewswire/ -- Mallinckrodt plc and Endo, Inc. today announced that they have completed their merger to create a global, scaled, diversified therapeutics lead ...

Core Viewpoint - The merger between Mallinckrodt plc and Endo, Inc. is set to close in early August 2025, following the Irish High Court's ruling and shareholder approvals, aiming to create a diversified global therapeutics leader [1][2][3] Company Overview - Mallinckrodt is a global business with multiple subsidiaries focused on developing, manufacturing, marketing, and distributing specialty pharmaceutical products, particularly in areas like autoimmune and rare diseases, neonatal respiratory care, and gastrointestinal products [5] - Endo is a diversified pharmaceutical company dedicated to transforming insights into life-enhancing therapies, with a commitment to delivering essential medicines [7] Merger Details - The merger involves a stock and cash transaction, with Mallinckrodt's headquarters in Dublin serving as the global headquarters for the combined entity [1][2] - The companies plan to combine their generic pharmaceuticals businesses and Endo's sterile injectables business, with a future separation of these businesses subject to board approval [3] Leadership - Siggi Olafsson, President and CEO of Mallinckrodt, will continue in the same role for the combined company, emphasizing the opportunity for value creation for shareholders, customers, and employees [3] Advisory Teams - Mallinckrodt's financial advisor is Lazard, with legal counsel from Wachtell, Lipton, Rosen & Katz, Hogan Lovells, and Arthur Cox. Endo's financial advisor is Goldman Sachs & Co. LLC, with legal counsel from Davis Polk & Wardwell LLP, Paul, Weiss, Rifkind, Wharton & Garrison LLP, and A&L Goodbody LLP [4]